FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284443> ?p ?o ?g. }

• W4379284443 endingPage "551" @default.
• W4379284443 startingPage "551" @default.
• W4379284443 abstract "551 Background: In hormone-receptor positive (HR+) early breast cancer (EBC) adjuvant endocrine therapy (ET) significantly reduces recurrence and mortality. The most common way to estimate therapy adherence is the use of patient reported outcome measures. Yet, this method is inaccurate due to the social-desirability bias. We therefore aimed to analyze adherence to ET over the first 5 years of treatment by using claims data from a large German health insurance provider (AOK Baden-Wuerttemberg). Methods: Female patients diagnosed with HR+ EBC between July 1 st 2010 and December 31 st 2019 were included into the analysis. Adherence to ET was defined as the ratio of the summed number of pills of filled prescriptions for ET (either aromatase inhibitors or tamoxifen) and the duration of endocrine therapy in days (from the start of the first prescription after completion of surgery and chemotherapy, if applicable). ET administration was observed over 5 years. High/low adherence was defined as a ratio between 0.8 – 1 and 0 – 0.8, respectively. ET duration was divided into yearly intervals and adherence was calculated as above. Continuous high/low adherence was then defined as an adherence between 0.8 – 1 and 0 – 0.8 in each year. Distant recurrence-free survival (DRFS) was calculated from the day of the first diagnosis of EBC until onset of distant metastatic disease. Overall survival (OS) was defined as the period between first diagnosis of EBC until death. Results: In total, 20998 patients were included. 17006 patients (81%) were HR+. Regarding overall adherence during the first 5 years, average adherence was 0.81 ± 0.26, with 72% of all HR+ patients showing high adherence to ET. Of 17006 HR+ EBC patients, 8363 (49%) showed a continuous high adherence to ET and 1731 (10%) showed a continuous low adherence to ET over 5 consecutive years. Continuous adherence to endocrine therapy had a significant impact on DRFS (HR: 0.61; 95% CI: 0.52 - 0.71; p < 0.0001) and OS (HR: 0.52; 95% CI: 0.46 -0.59; p < 0.0001). The 10-year OS rate was 79% / 64% for patients with continuous high / low adherence to endocrine therapy. Conclusions: As measured by the number of prescribed pills, adherence during the first 5 years of endocrine therapy was higher than expected by literature. Continuous adherence to ET over 5 years has a significant impact on OS and DRFS. Future research should focus on identifying factors that influence therapy adherence in HR+ EBC patients." @default.
• W4379284443 created "2023-06-05" @default.
• W4379284443 creator A5005228994 @default.
• W4379284443 creator A5019276717 @default.
• W4379284443 creator A5023008141 @default.
• W4379284443 creator A5028882183 @default.
• W4379284443 creator A5030131864 @default.
• W4379284443 creator A5032608059 @default.
• W4379284443 creator A5056452155 @default.
• W4379284443 creator A5059250883 @default.
• W4379284443 creator A5061592451 @default.
• W4379284443 creator A5076317762 @default.
• W4379284443 creator A5077815272 @default.
• W4379284443 creator A5085385776 @default.
• W4379284443 creator A5086688447 @default.
• W4379284443 date "2023-06-01" @default.
• W4379284443 modified "2023-09-25" @default.
• W4379284443 title "Influence of adherence to adjuvant endocrine therapy in early breast cancer: Results from a large German real-world claims data analysis." @default.
• W4379284443 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.551" @default.
• W4379284443 hasPublicationYear "2023" @default.
• W4379284443 type Work @default.
• W4379284443 citedByCount "0" @default.
• W4379284443 crossrefType "journal-article" @default.
• W4379284443 hasAuthorship W4379284443A5005228994 @default.
• W4379284443 hasAuthorship W4379284443A5019276717 @default.
• W4379284443 hasAuthorship W4379284443A5023008141 @default.
• W4379284443 hasAuthorship W4379284443A5028882183 @default.
• W4379284443 hasAuthorship W4379284443A5030131864 @default.
• W4379284443 hasAuthorship W4379284443A5032608059 @default.
• W4379284443 hasAuthorship W4379284443A5056452155 @default.
• W4379284443 hasAuthorship W4379284443A5059250883 @default.
• W4379284443 hasAuthorship W4379284443A5061592451 @default.
• W4379284443 hasAuthorship W4379284443A5076317762 @default.
• W4379284443 hasAuthorship W4379284443A5077815272 @default.
• W4379284443 hasAuthorship W4379284443A5085385776 @default.
• W4379284443 hasAuthorship W4379284443A5086688447 @default.
• W4379284443 hasConcept C121608353 @default.
• W4379284443 hasConcept C126322002 @default.
• W4379284443 hasConcept C143998085 @default.
• W4379284443 hasConcept C2426938 @default.
• W4379284443 hasConcept C2777176818 @default.
• W4379284443 hasConcept C2777982462 @default.
• W4379284443 hasConcept C530470458 @default.
• W4379284443 hasConcept C71924100 @default.
• W4379284443 hasConcept C81603835 @default.
• W4379284443 hasConcept C98274493 @default.
• W4379284443 hasConceptScore W4379284443C121608353 @default.
• W4379284443 hasConceptScore W4379284443C126322002 @default.
• W4379284443 hasConceptScore W4379284443C143998085 @default.
• W4379284443 hasConceptScore W4379284443C2426938 @default.
• W4379284443 hasConceptScore W4379284443C2777176818 @default.
• W4379284443 hasConceptScore W4379284443C2777982462 @default.
• W4379284443 hasConceptScore W4379284443C530470458 @default.
• W4379284443 hasConceptScore W4379284443C71924100 @default.
• W4379284443 hasConceptScore W4379284443C81603835 @default.
• W4379284443 hasConceptScore W4379284443C98274493 @default.
• W4379284443 hasIssue "16_suppl" @default.
• W4379284443 hasLocation W43792844431 @default.
• W4379284443 hasOpenAccess W4379284443 @default.
• W4379284443 hasPrimaryLocation W43792844431 @default.
• W4379284443 hasRelatedWork W2028037474 @default.
• W4379284443 hasRelatedWork W2057553101 @default.
• W4379284443 hasRelatedWork W2090720126 @default.
• W4379284443 hasRelatedWork W2113911245 @default.
• W4379284443 hasRelatedWork W2172254302 @default.
• W4379284443 hasRelatedWork W2401100240 @default.
• W4379284443 hasRelatedWork W2416022804 @default.
• W4379284443 hasRelatedWork W2464051959 @default.
• W4379284443 hasRelatedWork W2942716128 @default.
• W4379284443 hasRelatedWork W2181705735 @default.
• W4379284443 hasVolume "41" @default.
• W4379284443 isParatext "false" @default.
• W4379284443 isRetracted "false" @default.
• W4379284443 workType "article" @default.